Agoracom Blog Home

Posts Tagged ‘Psychedelic’

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 9:22 AM on Saturday, September 18th, 2021

A weekly summary of Novamind news and media, including the announcement of our selection as a research site for Karuna Therapeutics.

September 14, 2021

What Is Psycholytic Ketamine Assisted Psychotherapy?

In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison are joined by returning guest, Vhari Macbeth to discuss psycholytic ketamine-assisted psychotherapy (KAP).

Learn more, subscribe and catch up on previous episodes you may have missed at psychedelictherapyfrontiers.com

View all media

Novamind to Serve as Research Site for Karuna Therapeutics Late-Stage Clinical Trial

We are pleased to announce that our wholly owned subsidiary, Cedar Clinical Research has been selected as a research site for a clinical trial sponsored by Karuna Therapeutics, Inc., a clinical-stage neuroscience biopharmaceutical company

The phase III study will evaluate the investigational therapy KarXT for the treatment of schizophrenia, a serious and potentially disabling condition affecting approximately 20 million people worldwide.

Dr. Reid Robison, Novamind’s Chief Medical Officer and Principal Investigator at CCR said, “We need more innovation in this field and I’m hopeful to see compounds like KarXT that have new ways of acting on the brain and the potential for improved efficacy and side effect profiles.”

September 13, 2021

View all press releases

Legalising Illicit Therapies: Why Psychedelics Could Be The Most Important Mental Health Breakthrough Of The 21st Century

As psychedelics continue to break free from the stigma surrounding them, more and more people are seeing the promise these drugs have in changing the way we treat mental health. “Recent trials are showing that psychedelics are proving not only successful but also incredibly effective when stacked up against traditional forms of treatment, with one recent trial reporting that they are up to four times more effective than antidepressants.”

The DEA Seeks To Increase Federal Production Limits For Psilocybin And Marijuana Research

In a big step forward for psychedelic research, the DEA is set to increase limits for psilocybin. From the DEA: “DEA firmly believes in supporting regulated research of schedule I controlled substances.” We look forward to increased research and have a dedicated psychedelic contract research organization (CRO) in Cedar Clinical Research, capable of studying promising new treatments.

Follow @novamind_inc on Instagram

For further information, email us: 
[email protected]

Was this email forwarded to you?
Subscribe to our weekly newsletter

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 8:54 AM on Saturday, September 11th, 2021

A weekly summary of Novamind news and media, including the announcement of our uplisting to the OTCQB Market and much more.

September 7, 2021

Treating Trauma with Psychedelic-Assisted Psychotherapy

In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison are joined by Hannah Cross to discuss how psychedelic-assisted psychotherapy is used to treat trauma.

August 31, 2021

Treating Eating Disorders with Ketamine-Assisted Psychotherapy

In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison discuss how ketamine-assisted psychotherapy is used to treat eating disorders

Learn more, subscribe and catch up on previous episodes you may have missed at psychedelictherapyfrontiers.com

View all media

Novamind Uplists to OTCQB Venture Market

We pleased to announce our common shares have been approved for trading under the ticker symbol “NVMDF” on the OTCQB® Venture Market, a U.S. trading platform operated by the OTC Markets Group, Inc.

“With this listing, we look forward to expanding Novamind’s presence in the U.S. and deepening our relationships with a broad base of institutional and retail investors.” said Yaron Conforti, CEO and Director.

September 9, 2021

Novamind to Present at H.C. Wainwright 23rd Annual Global Investment Conference

CEO and Director, Yaron Conforti, will present the Company’s business model focused on growing a national network of psychiatry clinics and clinical research sites to rapidly scale access to psychedelic medicine.

Learn more about the Conference and register to schedule a one-on-one meeting with Novamind’s management here.

September 8, 2021

View all press releases

The Worldview-Changing Drugs Poised to Go Mainstream

BBC Future covers the experience, culture and future of psychedelics and “what might follow if psychedelics become mainstream.” It’s a popular theme in this week’s roundup: what the world will look like after the psychedelic revolution. “Psychedelics offer something that few other things can: an experience well beyond what our everyday reality could conceive or expect.” With such life changing drugs and therapies becoming available, there’s no doubt the future will look a lot different.

Neurocognitive Effects of Ketamine for Depression Examined

This article delivers more positive news about ketamine and esketamine, which we currently use in our Cedar Psychiatry clinics. Learn more about how we use these powerful drugs here. “Use of ketamine and esketamine for their antidepressant effects does not seem to have harmful neurocognitive effects in individuals with treatment-resistant depression, according to a review published online Aug. 5 in the Harvard Review of Psychiatry.”

Psychedelic Treatments Are Here, But Doctors Aren’t Prepared

Rick Doblin and Jennifer Ouyang Altman lay out the potential risks of not having standardized psychedelic education for providers. It’s a problem that will arise as psychedelics continue to move into the mainstream. It’s one reason why education is such a big component of our mission to increase access to psychedelic medicine. On the Psychedelic Therapy Frontiers podcast, we cover topics across the spectrum from trip-sitting to treating trauma with psychedelic-assisted psychotherapy. Another way we’re helping address this issue is by creating psychedelic treatment protocols, sharing best-in-class techniques and procedures with the wider population. Learn more here.

Follow @novamind_inc on Instagram

For further information, email us: 
[email protected]

Was this email forwarded to you?
Subscribe to our weekly newsletter

VIDEO – Biomind Labs (BMND : NEO) Is Developing The Next Generation of Medicines For The 21st Century – The Pharmaceutical Side of Psychedelics

Posted by AGORACOM-JC at 4:40 PM on Wednesday, August 25th, 2021
Biomind Labs Inc. Completes Reverse Take-Over Transaction | Business Wire

Alejandro Antalich, CEO of Biomind. “We, both, are driven by innovation. At Biomind, our objective is to change the course of medicine by assisting doctors in potentially saving more lives and providing a better quality of life to millions of people suffering from addiction, chronic pain, depression, anxiety, and other mental health disorders.

Biomind Labs is Developing the next generation of medicines for the 21st century … the pharmaceutical side of psychedelics

THE PROBLEM

● Depression and anxiety cost the global economy US$ 1 trillion each year

  • ~ 20% of the world’s children and adolescents have a mental health condition
  • Suicide is the second leading cause of death among 15-29 year-olds
  • 13% rise in mental health conditions & substance use disorders in last decade (to 2017)
  • Mental health conditions now cause 1 in 5 years lived with disability

#Psychedelics are going to go through a parabolic, paradigm shifting growth in the next 5 years because of their ability to treat anxiety and depression amongst other things

More than 80% of the global population prefers natural products as sources of new drug candidates …

and that is good because Biomind’s vertical integration approach – Transforming natural psychotropic compounds into pharmaceuticals  – creating drug therapies that harness the medicinal power of natural psychedelic compounds

1 indication is already in Phase 2 … 3 indications in Phase 2 by end 2021 … 3 in Phase 3 by end 2022.

Sit back, relax and watch this powerful interview with Alejandro Antalich, Chief Executive Officer of Biomind Labs.

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 9:03 AM on Saturday, August 7th, 2021

A weekly summary of Novamind news and media, including the announcement of our new VP of Communications and much more.

FEATURES August 6, 2021

A Step Forward for Mental Health

Where other treatments for depression have failed, ketamine has changed lives. Chief Medical Officer Dr. Reid Robison spoke to Leafly about how ketamine is changing mental healthcare.

“Ketamine is now emerging as a powerful catalyst to accelerate the healing and recovery process in individuals suffering from a wide array of mental health symptoms.”

OPINION August 3, 2021

Why Do We Self-Sabotage?

In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer, Vhari MacBeth, and Derick Moody explore the curious phenomenon of self-sabotage.

Learn more, subscribe and catch up on previous episodes you may have missed at psychedelictherapyfrontiers.com 

FEATURES August 3, 2021

Predicting the Boom

Business insider covers our business model and why VCs are bullish on the psychedelic boom.

“2021 and the vast majority of 2022 will be laying infrastructure groundwork for the coming global industry to emerge”

View all media

Novamind Strengthens Mental Health Expertise, Adds Communications Leader

We are pleased to announce the appointment of Samantha DeLenardo as Vice President, Communications to lead Novamind’s communications, marketing and investor relations.

“At Novamind, we care deeply about the clients and families we serve,” said DeLenardo. “We are prepared to meet this transformative moment for psychedelics and mental health, thanks in large part to the courage and years of advocacy by people with lived expertise and medical practitioners. Novamind understands both the responsibility and opportunity before us, and I look forward to sharing the Company’s story with the world.”

August 6, 2021

View all press releases

Usona Institute Breaks Ground for Global Center in Psychedelic Science

In a big step forward for psychedelics, Usona Institute announced the groundbreaking of a Global Center in Psychedelic Science. The campus will “support a blend of disciplines in psychedelic science and education.” It’s another example of momentum building around the truly extraordinary therapeutic potential of psychedelics.

TheraPsil’s Proposed ‘Access to Psilocybin for Medical Purposes Regulations’

Words have not been minced. CEO Spencer Hawkswell comments on the current exemptions for the terminally ill in Canada, “We are going to be lobbying hard to get those regulations set into law to make sure that Canadians can realize their rights to psilocybin.” We look forward to that access expanding to all Canadians.

Follow @novamind_inc on Instagram

 
 

For further information, contact:

Bill Mitoulas
Investor Relations
Telephone: +1 (416) 479 9547
Email: [email protected]

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 8:17 AM on Saturday, July 31st, 2021

A weekly summary of Novamind news and media, including the announcement of the opening of our fifth location in Draper, Utah.

OPINION July 27, 2021

The Art and Science of Psychedelic Trip-Sitting

In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Reid Robison, Dr. Steve Thayer, and Derick Moody, discuss the art and science of psychedelic trip-sitting.

Visit us at psychedelictherapyfrontiers.com to learn more, subscribe and catch up on previous episodes you may have missed.

FEATURES July 28, 2021

Potential for Exponential Increase in Healing

Gaining insurance coverage for off-label ketamine treatment of depression could help exponentially more people in their healing journeys. Off-label medicine isn’t covered by insurance.

“Our health care system does acknowledge and allow us to use medicines off-label. Probably 20 percent or more of all prescriptions are given that way.” – Novamind Chief Medical Officer Dr. Reid Robison

View all media

Novamind Opens 5th Location Specialized in Integrative Psychiatry for Patients with Treatment-Resistant Conditions

We are pleased to announce the completed the construction of a new clinic focused on integrative psychiatric care and clinical research in Draper, Utah. With the opening of the New Clinic, Novamind is on track to open four new locations in Utah by September 2021, doubling the size of its network to eight clinics.

“We are on a mission to reduce suffering and optimize wellness and are committed to shaping the future of psychedelic medicine in a responsible and accessible way,” said Dr. Reid Robison, Novamind’s Chief Medical Officer.

July 29, 2021

View all press releases

Back to the future: Psychedelic drugs in psychiatry

In an article for Harvard Health, Peter Grinspoon, MD, covers how psychedelics work, evidence for using psychedelics medicinally and the pros and cons. It’s an interesting read given his personal history with psychedelics, which dates back to when he was 14 and reading “Psychedelic Drugs Reconsidered.” He remembers the book urging “an open-minded reappraisal about the therapeutic potential of this class of drugs.” Anyone involved in psychedelics knows that not all conversations on the topic are open-minded. It’s why part of the mission to provide safe, legal access to psychedelics also includes an educational component. The more we can destigmatize psychedelics, the faster we can continue to push the renaissance forward. 

Psychedelic trips could soon be part of therapy — here’s what those sessions will look like

Have you ever wondered what psychedelic therapy looks like? This article provides an insight into that process. “You don’t just get thrown into it,” (Jennifer) Mitchell says. “It’s not Burning Man or something. It’s very thoughtful.” And it’s something we take very seriously at our Cedar Psychiatry clinics. We recently posted a blog about psychedelics and safety considerations. Read it here.

Follow @novamind_inc on Instagram

 
 

For further information, contact:

Bill Mitoulas
Investor Relations
Telephone: +1 (416) 479 9547
Email: [email protected]

Awakn Life Sciences to Commence Trading on the NEO Exchange Under the Symbol $AWKN

Posted by AGORACOM-JC at 12:18 PM on Wednesday, June 23rd, 2021
  • Strategic focus on developing and delivering psychedelic medicines to treat Addiction.
  • Strong psychedelic drug development pipeline targeting Addiction.
  • First mover advantage for clinics in the UK and the EU with 400m people and CAD$25TR GDP.
  • The leading research and clinical team in the industry focused on using psychedelics to treat Addiction.
  • Multiple scalable revenue streams across drug development and clinical delivery.

Toronto, Ontario–(June 23, 2021) – Awakn Life Sciences Corp. (NEO: AWKN) (“Awakn” or the “Company“) a biotechnology company with clinical operations developing, and delivering psychedelic medicines to treat Addiction, is pleased to announce it will begin trading today, June 23, 2021, on the NEO Exchange Inc. (the “NEO”) under the symbol “AWKN”.

“Listing on the NEO is an important milestone for Awakn to continue to build on our dual strategic focus of developing psychedelic drugs, therapies, and enabling technologies to treat Addiction, and delivering psychedelic treatments for Addiction in our clinics,” said Awakn CEO, Anthony Tennyson. “The NEO listing will enable us to accelerate the execution of our drug discovery, therapy development, advanced analytics, and open clinic roll out programs.”

The listing follows the successful completion of the previously announced reverse takeover of a Canadian public company, 2835517 Ontario Ltd., by Toronto-based Awakn Life Sciences Inc. The public company was subsequently renamed Awakn Life Sciences Corp. in connection with the reverse takeover and the listing on the NEO. Additionally, the Company raised gross proceeds of approximately USD$8.3 million through a brokered private placement.

Awakn engaged Canaccord Genuity Corp. and Eight Capital as co-lead agent and joint bookrunners to complete the brokered financing. In connection with the transaction, 2835517 Ontario Ltd. was de-listed from the NEX board of the TSX Venture Exchange.

A filing statement with information about Awakn prepared in accordance with the policies of the NEO is available on SEDAR at www.sedar.com.

About Awakn Life Sciences

Awakn Life Sciences is a biotechnology company with clinical operations, researching, developing, and delivering psychedelic medicine to better treat Addiction. Awakn’s team consists of world leading chemists, scientists, psychiatrists, and psychologists who are developing and advancing the next generation of psychedelic drugs, therapies, and enabling technologies to treat Addiction. Awakn will also deliver evidence backed psychedelic therapies for Addiction in clinics in the UK and Europe and through licencing partnerships globally.

www.awaknlifesciences.com | Twitter | LinkedIn | Facebook

Forward Looking Statements

This news release contains certain forward-looking information and forward-looking statements, as defined in applicable securities laws (collectively referred to herein as “forward-looking statements”). Forward-looking statements reflect current expectations or beliefs regarding future events or the Company’s future performance. All statements other than statements of historical fact are forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “continues”, “forecasts”, “projects”, “predicts”, “intends”, “anticipates”, “targets” or “believes”, or variations of, or the negatives of, such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “should”, “might” or “will” be taken, occur or be achieved, including statements relating to the proposed NEO listing, and the business of the Company. All forward-looking statements, including those herein are qualified by this cautionary statement.

Although the Company believes that the expectations expressed in such statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the statements. There are certain factors that could cause actual results to differ materially from those in the forward-looking information. These include: whether conditions to the listing on NEO will be satisfied; the business plans and strategies of the Company, the ability of the Company to comply with all applicable governmental regulations in a highly regulated business; the inherent risks in investing in target companies or projects which have limited or no operating history and are engaged in activities currently considered illegal in some jurisdictions; changes in laws; limited operating history; reliance on management; requirements for additional financing; competition; inconsistent public opinion and perception regarding the medical-use of psychedelic drugs; and regulatory or political change. Readers are cautioned that the foregoing list of factors is not exhaustive of the factors that may affect forward-looking statements. Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release speak only as of the date of this news release or as of the date or dates specified in such statements.

Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking information. For more information on the Company, investors are encouraged to review the Company’s public filings on SEDAR at www.sedar.com. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.

This news release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States. The Company’s and Awakn’s securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Investor Enquiries:
KCSA Strategic Communications
Valter Pinto / Tim Regan
Phone: +1 (212) 896-1254
[email protected]

Media Enquiries:
America and Canada: KCSA Strategic Communications
Anne Donohoe
[email protected]

Rest of World: ROAD Communications
Paul Jarman / Anna Ramsey
[email protected]

VIDEO – Awakn Life Sciences Corp. $AWKN Is Addressing The Multi-Billion Dollar #Addiction Treatment Industry With #Psychedelics

Posted by AGORACOM-JC at 12:14 PM on Wednesday, June 23rd, 2021

To understand Awakn you first have to understand that …. Psychedelics are going to go through a parabolic, paradigm shifting growth in the next 5 years because of their ability to treat anxiety, depression and addiction … amongst other things Awakn Life Sciences is a biotechnology company with clinical operations developing, and delivering psychedelic medicine to better treat Addiction.  

Awakn has a dual strategic focus: 

  1. Development: Research & developing the next generation of psychedelic drugs, therapies, and enabling technologies to better treat Addiction.
  2. Delivery: Awakn will deliver evidence backed psychedelic therapies for Addiction in clinics in the UK and Europe and through licensing partnerships globally. 

Notable Highlights include: 

  • Strategic focus on better treating Addiction with psychedelics.
  • World leading team focused on psychedelic drug and therapy research. 
  • Strong drug and therapy development pipeline, specifically targeting Addiction.
  • Clinics, which will be the UK and EU’s leading medical psychedelic therapy delivery 
  • Closed $8.3M June 8
  • BRAND NEW LISTING … commencing trading on NEO

Sit back, relax and watch this powerful interview with CEO Anthony Tennyson. 

Novamind $NM.ca $NVMDF Announces Participation at the Planet MicroCap Showcase on April 20 – 22, 2021 $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 2:06 PM on Tuesday, April 20th, 2021
  • Will present at the SNN Planet MicroCap Showcase on Thursday, April 22nd at 10:00 AM EST.

TORONTO, ON / April 20, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) (“Novamind” or the “Company”), a leading mental health company specialized in psychedelic medicine, will present at the SNN Planet MicroCap Showcase on Thursday, April 22nd at 10:00 AM EST.

Yaron Conforti, Novamind’s CEO, will present at the event, outlining Novamind’s vision for scaling access to psychedelic medicine and taking questions from investors. The presentation will cover Novamind’s clinical and research infrastructure, recent milestones, and its expansion plans for 2021.

Novamind will also be featured on a panel discussion titled, “Past, Present and Future of Psychedelics” on Tuesday, April 20th at 7:00 PM EST.

Presentation information:

To tune in to the webcast, please visit this link.

To book a one-on-one investor meeting with Novamind or to watch the Company’s presentation, please register for the virtual event here. One-on-one meetings will be scheduled and conducted via private, secure video conference through the conference event platform.

About Novamind

Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca.

About SNN.Network

SNN.Network is your multimedia financial news platform for discovery, transparency and due diligence. This is your one-stop hub to find new investment ideas, check in on watchlist, gather the most up-to-date information on the Small-, Micro-, Nano-Cap market with the goal to help you towards achieving your wealth generation goals. Follow the companies you want to know more about; read and watch content from your favorite finance and investing influencers; create your own watchlist and screen for ideas you’re interested in; find out about investor conferences you want to attend – all here on SNN.Network.

Contact Information:

Novamind
Yaron Conforti, CEO and Director
Telephone: +1 (647) 953 9512

Bill Mitoulas, Investor Relations
Email: [email protected]

Novamind $NM.ca $NVMDF to Present at the Planet MicroCap Virtual Event on April 22, 2021 $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 12:18 PM on Monday, April 19th, 2021
  • Will present at the SNN Planet MicroCap Showcase on Thursday, April 22nd at 10:00 AM EST.
  • Yaron Conforti, Novamind’s CEO, will present at the event, outlining Novamind’s vision for scaling access to psychedelic medicine and taking questions from investors.
  • The presentation will cover Novamind’s clinical and research infrastructure, recent milestones, and its expansion plans for 2021.

TORONTO, ON / April 19, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) (“Novamind” or the “Company”), a leading mental health company specialized in psychedelic medicine, will present at the SNN Planet MicroCap Showcase on Thursday, April 22nd at 10:00 AM EST.

Yaron Conforti, Novamind’s CEO, will present at the event, outlining Novamind’s vision for scaling access to psychedelic medicine and taking questions from investors. The presentation will cover Novamind’s clinical and research infrastructure, recent milestones, and its expansion plans for 2021.

Novamind will also be featured on a panel discussion titled, “Past, Present and Future of Psychedelics” on Tuesday, April 20th at 7:00 PM EST.

Presentation information:

To tune in to the webcast, please visit this link.

To book a one-on-one investor meeting with Novamind or to watch the Company’s presentation, please register for the virtual event here. One-on-one meetings will be scheduled and conducted via private, secure video conference through the conference event platform.

About Novamind

Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca.

Contact Information

Novamind
Yaron Conforti, CEO and Director
Telephone: +1 (647) 953 9512

Bill Mitoulas, Investor Relations
Email: [email protected]

SOURCE: Novamind Inc.

Novamind $NM.ca $NVMDF Increases Strategic Investment in Bionomics $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 8:37 AM on Tuesday, April 13th, 2021
  • Announced that it has increased its strategic investment in Bionomics Limited (“Bionomics”) (ASX: BNO | OTCQB: BNOEF | Germany: AU000000BNO5), a biopharmaceutical company dedicated to developing better treatments for central nervous system disorders.
  • Investment supports phase IIb clinical trial examining novel PTSD treatment

TORONTO, ON / April 13, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) (“Novamind” or the “Company”), a leading mental health company specialized in psychedelic medicine, is pleased to announce that it has increased its strategic investment in Bionomics Limited (“Bionomics”) (ASX: BNO | OTCQB: BNOEF | Germany: AU000000BNO5), a biopharmaceutical company dedicated to developing better treatments for central nervous system disorders.

Novamind purchased an additional 951,133 common shares at AU$0.145 per share for a total investment of AU$137,914 (approximately CAN$132,000) in Bionomics’ recently completed rights offering (the “Rights Offering”). In addition to Novamind’s initial AU$827,486 investment (approximately CAN$810,000) announced on February 11th, 2021, Novamind has invested in Bionomics a total of AU$965,400 (approximately CAN$942,000). Bionomics shares closed at AU$0.20 on April 12th, 2021, a 38% return (unrealized) on Novamind’s total investment.

Proceeds from the Rights Offering will support the initiation of Bionomics’ phase IIb clinical trial for BNC210, a drug that has received Fast Track Designation from the U.S. Food and Drug Administration for the treatment of post-traumatic stress disorder (PTSD). Bionomics is evaluating Cedar Clinical Research, a wholly owned subsidiary of Novamind, as a research site for the BNC210 clinical trial that is anticipated to start mid-2021.

“We are pleased to support the development of a new treatment for PTSD and to be evaluated as a clinical research site for the phase IIb clinical trial of BNC210,” said Yaron Conforti, CEO and Director of Novamind. “Our expertise in clinical research for mental health therapeutics is widely recognized in the biopharmaceutical industry, as demonstrated by our collaboration with Bionomics and recent partnership with Merck.”

To learn more about Cedar Clinical Research, please visit cedarclinicalresearch.com.

About Novamind
Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca.

About Bionomics

Bionomics is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates. Bionomics’ lead drug candidate BNC210, currently in development for initiation of a second phase II trial for the treatment of PTSD, is a novel, proprietary negative allosteric modulator of the alpha-7 (α7) nicotinic acetylcholine receptor. Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada). To learn more, please visit bionomics.com.au.

Contact Information
Novamind
Yaron Conforti, CEO and Director
Telephone: +1 (647) 953 9512

Bill Mitoulas, Investor Relations
Email: [email protected]

Forward-Looking Statements
This news release contains forward-looking statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations including the risks detailed from time to time in the Company’s public disclosure. The reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable laws.

SOURCE: Novamind Inc.